Drug intelligence / Profile preview

siemuron

Development stage: Unknown
Lead developer: Xijing Hospital
Modality: Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

Siemuron is a skin lotion developed by Xijing Hospital for the prevention and treatment of radiation dermatitis after head and neck tumor and breast cancer. It is applied topically and is currently marketed, considered a conventional treatment for which patients pay out-of-pocket.

Other names: 赛肤润

Targets

TP53RK (TP53 regulating kinase)

Beyond the preview

Go deeper on siemuron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on siemuron.

Explore the full profile